Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

Mary E. Rinella

doi:10.1002/hep.24634

Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

Mary E. Rinella^*

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Editorial › peer-review

16 Scopus citations

Original language	English (US)
Pages (from-to)	1118-1120
Number of pages	3
Journal	Hepatology
Volume	54
Issue number	4
DOIs	https://doi.org/10.1002/hep.24634
State	Published - Oct 2011

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hep.24634

Cite this

@article{6363d30f475c4f8e991509bb29e93e30,

title = "Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?",

author = "Rinella, {Mary E.}",

year = "2011",

month = oct,

doi = "10.1002/hep.24634",

language = "English (US)",

volume = "54",

pages = "1118--1120",

journal = "Hepatology",

issn = "0270-9139",